Microbiome Therapeutics Market Analysis and Forecast, 2022-2032

1
Global Microbiome Therapeutics Market-
A Global and Regional Analysis
res
Table of Content
T E K R A M
S C I T U E P A R E H T E M O I B O
R C I M
Focus on Target Therapies, Region (10
Countries), and Competitive Landscape Analysis
and Forecast 2022-2032 June 2022
L A B O L 1 G All rights reserved at BIS
Research Inc.
2
BIS Research is a leading market intelligence and
technology research company. BIS Research
publishes in- depth market intelligence reports
focusing on the market estimations, technology
analysis, emerging high- growth applications,
deeply segmented granular country-level market
data and other important market parameters
useful in the strategic decision making for
senior management. BIS Research provides
multi-client reports, company profiles,
databases, and custom research services.
GLOBAL MICROBIOME THERAPEUTICS MARKET
Copyright 2022 BIS Research Inc. All Rights
Reserved. This document contains highly
confidential information and is the sole property
of BIS Research. Disclosing, copying,
circulating, quoting, or otherwise reproducing
any or all contents of this document is strictly
prohibited. Access to this information is
provided exclusively for the benefit of the
people or organization concerned. It may not be
accessed by or offered, whether for sale or
otherwise, to any third party.
2
3
Table of Content Executive Summary
..................................................
........................20 1. Market Definition
..................................................
.....................24 1.1 Inclusion and
Exclusion Criteria ...............................
.....................................24 2. Researc
h Scope ..........................................
..............................25 2.1 Target
Audience..........................................
..................................................
...26 2.2 Key Questions Answered in the
Report............................................
.............27 3. Research Methodology
..................................................
............28 3.1 Global Microbiome
Therapeutics Research Methodology................
..........28 3.2 Primary Data Sources
..................................................
...................................29 3.3 Secondar
y Data Sources ...................................
.............................................29 3.
4 Market Estimation Model.........................
..................................................
......30 3.5 Criteria for Company
Profiling.........................................
...............................32 4. Market
Overview..........................................
..............................33 4.1 Market Size
and Future Growth Potential ......................
................................33
4.2 Historical Trends ............................
..................................................
...............34 5. Industry Insights
..................................................
......................35 5.1 Regulatory Landscape
..................................................
..................................35 5.1.1
Regulatory Requirements for Live Biotherapeutic
Products (LBPs) ......35 5.1.2 Quality Check
of LBPs ..........................................
......................................35 5.1.3
FDA Approved Fecal Microbiota Transplantation
(FMT) Quality Check Procedure ...................
..................................................
....................36 5.2 Patent Landscape
..................................................
..........................................37 5.2.1
Patent Filing Analysis ........................
..................................................
.......37 5.2.2 Key Players Patent Portfolio
..................................................
....................38 5.2.3 Key Players Patent
Expiration Analysis ..............................
......................40 5.3 Partnership
Landscape ........................................
...........................................41 5.4
Government Initiatives ...........................
..................................................
.......42 5.5 Impact of COVID-19 on the Global
Microbiome Therapeutics Market.........44 5.5.1
Clinical Trial Disruptions and Resumptions
.............................................44 3
GLOBAL MICROBIOME THERAPEUTICS MARKET
4

• 6. Market Dynamics ...............................
  ........................................46
• 6.1 Market Drivers...........................
  ..................................................
  .....................46
• Growing Strategic Activities in Microbiome
  Therapeutics Segment ......46
• Potential of Microbiome Therapeutics to Address
  Unmet Needs of Existing Treatment
  Options...........................................
  .............................47
• Microbiome Therapeutic Products as a Safer
  Alternative to Conventional Drug Treatments
  ..................................................
  ................47
• 6.2 Market Restraints........................
  ..................................................
  ...................48
• 6.2.1 Lack of Uniformed Standardized Regulatory
  Guidelines.........................48 6.2.2
  Associated Safety Issues with LBPs
  ..................................................
  .......48 6.2.3 Storage Issues with Live
  Micro-Organisms ..................................
  ............48
• 6.2.4 Challenges Associated with Manufacturing of
  LBPs ...............................48 6.3
  Market Opportunities..............................
  ..................................................
  .......49
• 6.3.1 Need for Current Good Manufacturing
  Practice (cGMP) Certified Contract Manufacturing
  Facilities........................................
  ......................49
• 6.3.2 Growing Disease Dimension
  ..................................................
  ....................49
• 6.3.3 Entry of Major Players....................
  ..................................................
  ...........49
• 7. Clinical Trial Landscape.......................
  ......................................50
• 7.1 Microbiome Therapeutics Pipeline
  Landscape ........................................
  .....50
• 7.1.1 Competitive Landscaping
  ..................................................
  .........................50
• 7.1.2 Pipeline Analysis .........................
  ..................................................
  ..............54
• 7.1.2.1 By Development Phase .....................
  ..................................................
  .............. 54
• 7.1.2.2 By Route of Administration
  ..................................................
  .............................. 55
• 7.1.2.3 By Type of Microbiome Strategy............
  ..................................................
  .......... 56
• 7.1.2.4 By Indication ...........................
  ..................................................
  ......................... 57

GLOBAL MICROBIOME THERAPEUTICS MARKET
5

• 7.2.2.1 SER-109 Product Profile..................
  ..................................................
  ............... 65
• 7.2.3 RBX-2660 (Rebiotix Inc.)
  ..................................................
  ...........................68
• 7.2.3.1 RBX-2660 Product Profile.................
  ..................................................
  .............. 68
• 7.2.4 CH-106 (Caelus Health) ...................
  ..................................................
  ..........71
• 7.2.4.1 CH-106 Product Profile...................
  ..................................................
  ................ 71
• 7.2.5 LACTIN-V (Osel Inc.) .....................
  ..................................................
  ............73
• 7.2.5.1 LACTIN-V Product Profile.................
  ..................................................
  .............. 73
• 7.2.6 MaaT013 (MaaT Pharma).....................
  ..................................................
  ......73
• 7.2.6.1 MaaT013 Product Profile
  ..................................................
  ................................ 73
• 8. Competitive Insights ..........................
  ........................................74
• 8.1 Key Strategies and Developments
  ..................................................
  ...............74
• 8.2 Synergistic Activities .......................
  ..................................................
  .............74
• 8.3 Product Launch and Regulatory Approvals
  ..................................................
  75 8.4 Funding and Investment ...................
  ..................................................
  ............76
• 8.5 Mergers and Acquisitions .....................
  ..................................................
  ........77
• 8.6 Market Share Analysis ........................
  ..................................................
  ..........78
• 8.7 Growth-Share Analysis (Opportunity
  Mapping)..........................................
  ..79
• 8.7.1 By Region.................................
  ..................................................
  ..................79
• 8.7.2 By Company ...............................
  ..................................................
  ...............80
• Global Microbiome Therapeutics Market (by Target
  Therapy Area) ...................................
  ..................................................
  ....82

GLOBAL MICROBIOME THERAPEUTICS MARKET
6
10.2.2 U.S. ......................................
..................................................
.......................93 10.2.3 Canada
..................................................
..................................................
.....94 10.3 Europe ..............................
..................................................
..............................95 10.3.1 Overview
..................................................
..................................................
..95 10.3.2 France................................
..................................................
.........................98 10.3.3
Germany...........................................
..................................................
..........99 10.3.4 Sweden........................
..................................................
.............................100 10.3.5 U.K.
..................................................
..................................................
.........101 10.3.6 Italy ........................
..................................................
...................................102 10.3.7
Spain.............................................
..................................................
............102 10.3.8 Rest-of-Europe.............
..................................................
............................103 10.4 Asia-Pacific
(APAC)............................................
...........................................104 10.
4.1 Overview .....................................
..................................................
.............104 10.4.2 Japan ....................
..................................................
....................................106 10.4.3
Australia ........................................
..................................................
...........107 10.4.4 China ......................
..................................................
..................................109 10.4.5
India ............................................
..................................................
..............110 10.4.6 Rest-of-Asia-Pacific.....
..................................................
............................111 10.5 Rest-of-the-W
orld .............................................
.............................................112 1
0.5.1 Overview ...................................
..................................................
...............112 11. Competitive Benchmarking
and Company Profiles ...................
113 11.1 4D pharma plc ...........................
..................................................
...................113 11.1.1 Company Overview
..................................................
.................................113 11.1.2 Role
of 4D pharma plc in the Global Microbiome
Therapeutics Market..............................
..................................................
.........................113 11.1.3 Key
Competitors of the Company........................
....................................114 11.1.4
Financials .......................................
..................................................
..........115 11.1.5 Recent Developments
..................................................
.............................116 11.1.6 Analysts
Perspective ......................................
.........................................116 11.2
Seres Therapeutics, Inc. .........................
..................................................
....118
GLOBAL MICROBIOME THERAPEUTICS MARKET
6
7
11.2.1 Company Overview ..........................
..................................................
.......118 11.2.2 Role of Seres Therapeutics,
Inc. in the Global Microbiome Therapeutics
Market............................................
......................................118 11.2.3
Key Competitors of the Company....................
........................................119 11.2.4
Financials ......................................
..................................................
...........119 11.2.5 Recent Developments
..................................................
.............................121 11.2.6 Analyst
Perspective ......................................
............................................121 11
.3 Microbiotica...................................
..................................................
...............122 11.3.1 Company Overview
..................................................
.................................122 11.3.2 Role
of Microbiotica in the Global Microbiome
Therapeutics Market ..............................
..................................................
..............................122 11.3.3 Key
Competitors of the Company........................
....................................123 11.3.4
Recent Developments ..............................
.................................................1
23 11.3.5 Analysts Perspective
..................................................
.............................123 11.4 Enterome
..................................................
..................................................
....124 11.4.1 Company Overview
..................................................
.................................124 11.4.2 Role
of Enterome in the Global Microbiome Therapeutics
Market .......124 11.4.3 Key Competitors of the
Company...........................................
.................125 11.4.4 Recent Developments
..................................................
.............................125 11.4.5 Analysts
Perspective ......................................
.........................................125 11.5
Destiny Pharma plc ...............................
..................................................
......126 11.5.1 Company Overview
..................................................
.................................126 11.5.2 Role
of Destiny Pharma plc in the Global Microbiome
Therapeutics Market..............................
..................................................
.........................126 11.5.3 Key
Competitors of the Company........................
....................................127 11.5.4
Financials .......................................
..................................................
..........127 11.5.5 Recent Developments
..................................................
.............................128 11.5.6 Analysts
Perspective ......................................
.........................................129 11.6
Taisho Pharmaceutical Holdings ...................
..............................................130
11.6.1 Company Overview ..........................
..................................................
.......130
GLOBAL MICROBIOME THERAPEUTICS MARKET
7
8
11.6.2 Role of Taisho Pharmaceutical Holdings in
the Global Microbiome Therapeutics
Market............................................
......................................130 11.6.3
Key Competitors of the Company....................
........................................131 11.6.4
Financials.......................................
..................................................
..........131 11.6.5 Recent Developments
..................................................
.............................134 11.6.6 Analysts
Perspective ......................................
.........................................134 11.7
AOBiome Therapeutics, Inc. .......................
..................................................
135 11.7.1 Company Overview ......................
..................................................
...........135 11.7.2 Role of AOBiome
Therapeutics, Inc. in the Global Microbiome
Therapeutics Market...............................
..................................................
.135 11.7.3 Key Competitors of the
Company...........................................
.................136 11.7.4 Recent Developments
..................................................
.............................136 11.7.5 Analysts
Perspective ......................................
.........................................136 11.8
Finch Therapeutics Group, Inc. ...................
.................................................1
37 11.8.1 Company Overview .......................
..................................................
..........137 11.8.2 Role of Finch Therapeutics
Group, Inc. in the Global Microbiome
Therapeutics Market...............................
..................................................
.137 11.8.3 Key Competitors of the
Company...........................................
.................138 11.8.4 Financials
..................................................
.................................................1
38 11.8.5 Recent Developments ....................
..................................................
.........140 11.8.6 Analysts Perspective
..................................................
.............................140 11.9 Ferring
Pharmaceuticals ..................................
.............................................141 1
1.9.1 Company Overview ...........................
..................................................
......141 11.10 Rebiotix Inc. (A Subsidiary of
Ferring Pharmaceuticals) .........................
..141 11.10.1 Company Overview...................
..................................................
........141 11.10.2 Role of Rebiotix Inc. in the
Global Microbiome Therapeutics
Market............................................
..................................................
...........141 11.10.3 Key Competitors of the
Company ..........................................
...........142 11.10.4 Recent Developments........
..................................................
...............142 11.10.5 Analysts Perspective
..................................................
.......................143 11.11 MaaT Pharma
..................................................
...............................................144
GLOBAL MICROBIOME THERAPEUTICS MARKET
8
9
11.11.1 Company Overview..........................
..................................................
.144 11.11.2 Role of MaaT Pharma in the Global
Microbiome Therapeutics Market...................
..................................................
....................................144 11.11.3 Ke
y Competitors of the Company .....................
................................145 11.11.4 Financ
ials .............................................
...............................................145
11.11.5 Recent Developments......................
..................................................
.146 11.11.6 Analysts Perspective
..................................................
.......................146 11.12 Vedanta
Biosciences Inc...................................
............................................147 11
.12.1 Company Overview............................
.................................................1
47 11.12.2 Role of Vedanta Biosciences Inc. in
the Global Microbiome Therapeutics
Market............................................
......................................147 11.12.3
Key Competitors of the Company ...................
..................................148 11.12.4 Rece
nt Developments...................................
......................................148 11.12.5
Analysts Perspective ............................
.............................................148 1
1.13 OxThera AB .................................
..................................................
.................149 11.13.1 Company
Overview..........................................
...................................149 11.13.2 Rol
e of OxThera AB in the Global Microbiome
Therapeutics Market..............................
..................................................
.........................149 11.13.3 Key
Competitors of the Company .......................
..............................150 11.13.4 Recent
Developments......................................
...................................150 11.13.5 Ana
lysts Perspective ...............................
..........................................150 11.1
4 Pendulum Therapeutics .........................
..................................................
.....151 11.14.1 Company Overview.................
..................................................
..........151 11.14.2 Role of Pendulum
Therapeutics in the Global Microbiome
Therapeutics Market...............................
..................................................
.151 11.14.3 Key Competitors of the Company
..................................................
...152 11.14.4 Recent Developments................
..................................................
.......152 11.14.5 Analysts Perspective
..................................................
.......................152 11.15 Caelus Health
..................................................
...............................................153
11.15.1 Company Overview.........................
..................................................
..153
GLOBAL MICROBIOME THERAPEUTICS MARKET
9
10
11.15.2 Role of Caelus Health in the Global
Microbiome Therapeutics Market...................
..................................................
....................................153 11.15.3 Ke
y Competitors of the Company .....................
................................154 11.15.4 Recent
Developments.....................................
....................................154 11.15.5 An
alysts Perspective ..............................
...........................................154 11.
16 Quorum Innovations.............................
..................................................
.......156 11.16.1 Company Overview...............
..................................................
............156 11.16.2 Role of Quorum Innovations
in the Global Microbiome Therapeutics
Market............................................
......................................156 11.16.3
Key Competitors of the Company ...................
..................................157 11.16.4 Rece
nt Developments...................................
......................................157 11.16.5
Analysts Perspective ............................
.............................................157 1
1.17 Sanofi S.A..................................
..................................................
...................158 11.17.1 Company
Overview..........................................
...................................158 11.17.2 Rol
e of Sanofi S.A. in the Global Microbiome
Therapeutics Market..............................
..................................................
.........................158 11.17.3 Key
Competitors of the Company .......................
..............................159 11.17.4 Financia
ls ...............................................
.............................................159 1
1.17.5 Recent Developments........................
.................................................1
61 11.17.6 Analysts Perspective
..................................................
.......................162 11.18 DermBiont, Inc.
..................................................
............................................163 11
.18.1 Company Overview............................
.................................................1
63 11.18.2 Role of DermBiont, Inc. in the Global
Microbiome Therapeutics Market...................
..................................................
....................................163 11.18.3 Ke
y Competitors of the Company .....................
................................164 11.18.4 Recent
Developments.....................................
....................................164 11.18.5 An
alysts Perspective ..............................
...........................................164 11.
19 EnteroBiotix Ltd..............................
..................................................
.............166 11.19.1 Company
Overview..........................................
...................................166 11.19.2 Rol
e of EnteroBiotix Ltd in the Global Microbiome
Therapeutics Market..............................
..................................................
.........................166 10
GLOBAL MICROBIOME THERAPEUTICS MARKET
11
11.19.3 Key Competitors of the Company
..................................................
...167 11.19.4 Recent Developments................
..................................................
.......167 11.19.5 Analysts Perspective
..................................................
.......................167 11.20 YSOPIA
Bioscience .......................................
................................................16
8 11.20.1 Company Overview........................
..................................................
...168 11.20.2 Role of YSOPIA Bioscience in the Gl
obal Microbiome Therapeutics Market..............
..................................................
..................168 11.20.3 Key Competitors of
the Company ......................................
...............169 11.20.4 Recent
Developments......................................
...................................169 11.20.5 Ana
lysts Perspective ...............................
..........................................170 11.2
1 Winclove Probiotics ............................
..................................................
........171 11.21.1 Company Overview..............
..................................................
.............171 11.21.2 Role of Winclove Probioti
cs in the Global Microbiome Therapeutics
Market............................................
......................................171 11.21.3
Key Competitors of the Company ...................
..................................172 11.21.4 Rece
nt Developments...................................
......................................173 11.21.5
Analysts Perspective ............................
.............................................173 1
1.22 TargEDys ....................................
..................................................
..................174 11.22.1 Company
Overview..........................................
...................................174 11.22.2 Rol
e of TargEDys in the Global Microbiome
Therapeutics Market..............................
..................................................
.........................174 11.22.3 Key
Competitors of the Company .......................
..............................175 11.22.4 Recent
Developments......................................
...................................175 11.22.5 Ana
lysts Perspective ...............................
..........................................175 11.2
3 Evelo Biosciences, Inc. ........................
..................................................
.......176 11.23.1 Company Overview...............
..................................................
............176 11.23.2 Role of Evelo
Biosciences, Inc. in the Global Microbiome
Therapeutics Market...............................
..................................................
.176 11.23.3 Key Competitors of the Company
..................................................
...177 11.23.4 Financials ........................
..................................................
..................178 11.23.5 Recent
Developments......................................
...................................179
GLOBAL MICROBIOME THERAPEUTICS MARKET
12
11.23.6 Analysts Perspective ....................
..................................................
...179 11.24 BiomX ..............................
..................................................
.............................180 11.24.1 Company
Overview..........................................
...................................180 11.24.2 Ro
le of BiomX in the Global Microbiome Therapeutics
Market ......180 11.24.3 Key Competitors of the
Company ..........................................
...........181 11.24.4 Financials
..................................................
..........................................181
11.24.5 Recent Developments.......................
..................................................
182 11.24.6 Analysts Perspective
..................................................
.......................182 11.25 Biomica Ltd.
..................................................
.................................................1
84 11.25.1 Company Overview......................
..................................................
.....184 11.25.2 Role of Biomica Ltd. in the
Global Microbiome Therapeutics
Market............................................
..................................................
...........184 11.25.3 Key Competitors of the
Company ..........................................
...........185 11.25.4 Recent Developments........
..................................................
...............185 11.25.5 Analysts Perspective
..................................................
.......................185 11.26 Scioto
Biosciences, Inc..................................
...............................................186
11.26.1 Company Overview.........................
..................................................
..186 11.26.2 Role of Scioto Biosciences, Inc. in
the Global Microbiome Therapeutics
Market............................................
......................................186 11.26.3
Key Competitors of the Company ...................
..................................187 11.26.4 Rece
nt Developments...................................
......................................187 11.26.5
Analysts Perspective ............................
.............................................188 1
1.27 Lactobio A/S.................................
..................................................
................189 11.27.1 Company
Overview..........................................
...................................189 11.27.2 Rol
e of Lactobio A/S in the Global Microbiome
Therapeutics Market..............................
..................................................
.........................189 11.27.3 Key
Competitors of the Company .......................
..............................190 11.27.4 Recent
Developments......................................
...................................190 11.27.5 Ana
lysts Perspective ...............................
..........................................191 12.
Appendix ........................................
......................................... 192
GLOBAL MICROBIOME THERAPEUTICS MARKET
13
List of Figures
Figure 1 Figure 2 Global Microbiome Therapeutics Market Share (by Target Therapy Area), Million, 2021 Global Microbiome Therapeutics Market Share (by Region), Million, 2021 and 2032
Figure 3 Growth-Share Analysis (by Region), 2020-2021
Figure 4 Global Microbiome Therapeutics Market Segmentation
Figure 5 Global Microbiome Therapeutics Market Methodology
Figure 6 Primary Research Methodology
Figure 7 Bottom-Up Approach (Segment Wise Analysis)
Figure 8 Top-Down Approach (Segment-Wise Analysis)
Figure 9 Global Microbiome Therapeutics Market, Million, 2021-2032
Figure 10 Historical Evolution of Microbiome Therapeutics
Figure 11 Chemistry, Manufacturing, and Control (CMC) Information of LBPs by FDA
Figure 12 Patent Landscape of the Microbiome Therapeutics Market (by Region), 2019-2021
Figure 13 COVID-19 Impact on the Global Microbiome Therapeutics Market
Figure 14 Number of Strategic Activities in the Global Microbiome Therapeutics Market, 2019-2021
Figure 15 Number of Agreements for Leading Companies
Figure 16 Share of Microbiome Therapeutics Products in Global Clinical Trials (by Development Phase)
Figure 17 Share of Microbiome Therapeutics Pipeline Candidates (by Route of Administration)
Figure 18 Share of Microbiome Therapeutics Products (by Type of Microbiome Strategy)
Figure 19 Number of Microbiome Therapeutic Products in Global Clinical Trials (by Indication)
Figure 20 CP-101 Phase II Clinical Design for Recurrent C. diff. Infection (CDI)
Figure 21 CP-101 Phase III Clinical Design for Recurrent C. diff. Infection (CDI)
Figure 22 SER-109 Mechanism of Action
Figure 23 SER-109 Clinical Trial Details for Recurrent C. diff. Infection (CDI)
Figure 24 RBX-2660 Key Regulatory Milestones
Figure 25 RBX-2660 Clinical Progress for Recurrent C. Diff Infection (CDI)
Figure 26 RBX-2660 Clinical Trial Details for Recurrent C. diff. Infection (CDI)
Figure 27 CH-106 Clinical Design for Metabolic Syndrome/Prediabetes
Figure 28 Share of Key Developments and Strategies, January 2019October 2021
Figure 29 Share of Synergistic Activities (by Company), January 2019-October 2021
Figure 30 Share of Product Launch and Regulatory Approvals (by Company), January 2019-October 2021
GLOBAL MICROBIOME THERAPEUTICS MARKET
13
14
Figure 31 Figure 32 Figure 33 Share of Funding and Investment (by Company), January 2019-October 2021 Share of Mergers and Acquisitions (by Company), January 2019-October 2021 Market Share Analysis for the Global Microbiome Therapeutics Market, Million, 2020 and
2021
Figure 34 Growth-Share Analysis (by Region), 2020-2021
Figure 35 Growth-Share Analysis (by Company), 2020-2021
Figure 36 Global Microbiome Therapeutics Market (by Target Therapy Area), Million, 2021 and 2032
Figure 37 Number of Pipeline Candidates for Gastrointestinal and Infectious Diseases
Figure 38 Global Microbiome Therapeutics Market (Gastrointestinal and Infectious Diseases), Million, 2021-2032
Figure 39 Number of Pipeline Products for Skin Disorders
Figure 40 Global Microbiome Therapeutics Market (Skin Disorders), Million, 2021-2032
Figure 41 Number of Pipeline Products for Cancer Indications
Figure 42 Number of Pipeline Products for Other Indications
Figure 43 Global Microbiome Therapeutics Market (by Region), 2022-2032
Figure 44 Global Microbiome Therapeutics Market Share (by Region), Million, 2021-2032
Figure 45 North America Microbiome Therapeutics Market, Million, 2021-2032
Figure 46 North America Market Dynamics
Figure 47 North America Microbiome Therapeutics Market Share (by Country), Million, 2021 and 2032
Figure 48 U.S. Microbiome Therapeutics Market, Million, 2021-2032
Figure 49 Canada Microbiome Therapeutics Market, Million, 2021-2032
Figure 50 Europe Microbiome Therapeutics Market, Million, 2021-2032
Figure 51 Europe Market Dynamics
Figure 52 Europe Microbiome Therapeutics Market Share (by Country), Million, 2021 and 2032
Figure 53 France Microbiome Therapeutics Market, Million, 2021-2032
Figure 54 Germany Microbiome Therapeutics Market, Million, 2021-2032
Figure 55 Sweden Microbiome Therapeutics Market, Million, 2021-2032
Figure 56 U.K Microbiome Therapeutics Market, Million, 2021-2032
Figure 57 Italy Microbiome Therapeutics Market, Million, 2021-2032
Figure 58 Spain Microbiome Therapeutics Market, Million, 2021-2032
Figure 59 Rest-of-Europe Microbiome Therapeutics Market, Million, 2021-2032
Figure 60 Asia-Pacific Microbiome Therapeutics Market, Million, 2021-2032
Figure 61 Asia-Pacific Market Dynamics
GLOBAL MICROBIOME THERAPEUTICS MARKET
14
15
Figure 62 Asia-Pacific Microbiome Therapeutics Market Share (by Country), Million, 2021-2032
Figure 63 Japan Microbiome Therapeutics Market, Million, 2021-2032
Figure 64 Australia Microbiome Therapeutics Market, Million, 2021-2032
Figure 65 China Microbiome Therapeutics Market, Million, 2021-2032
Figure 66 India Microbiome Therapeutics Market, Million, 2021-2032
Figure 67 Rest-of-Asia-Pacific Microbiome Therapeutics Market, Million, 2021-2032
Figure 68 Rest-of-the-World Microbiome Therapeutics Market, Million, 2021-2032
Figure 69 4D pharma plc Product Portfolio
Figure 70 4D pharma plc Overall Financials, Million, 2019-2021
Figure 71 4D pharma plc RD Expenditure, Million, 2019-2021
Figure 72 Seres Therapeutics, Inc. Product Portfolio
Figure 73 Seres Therapeutics, Inc. Overall Financials, Million, 2019-2021
Figure 74 Seres Therapeutics, Inc. RD Expenditure, Million, 2019-2021
Figure 75 Microbiotica Product Portfolio
Figure 76 Enterome Product Portfolio
Figure 77 Destiny Pharma plc Product Portfolio
Figure 78 Destiny Pharma plc Overall Financials, Million, 2019-2021
Figure 79 Destiny Pharma plc RD Expenditure, Million, 2019-2021
Figure 80 Taisho Pharmaceutical Holdings Product Portfolio
Figure 81 Taisho Pharmaceutical Holdings Overall Financials, Million, 2019-2021
Figure 82 Taisho Pharmaceutical Holdings Net Revenue (by Segment), Million, 2019-2021
Figure 83 Taisho Pharmaceutical Holdings Net Revenue (by Region), Million, 2019-2021
Figure 84 Taisho Pharmaceutical Holdings RD Expenditure, Million, 2019-2021
Figure 85 AOBiome Therapeutics, Inc. Product Portfolio
Figure 86 Finch Therapeutics Group, Inc. Product Portfolio
Figure 87 Finch Therapeutics Group, Inc. Overall Financials, Million, 2019-2021
Figure 88 Finch Therapeutics Group, Inc. RD Expenditure, Million, 2020-2021
Figure 89 Rebiotix Inc. Product Portfolio
Figure 90 MaaT Pharma Product Portfolio
Figure 91 MaaT Pharma Overall Financials, Million, 2020-2021
Figure 92 MaaT Pharma RD Expenditure, Million, 2020-2021
Figure 93 Vedanta Biosciences Inc. Product Portfolio
Figure 94 OxThera AB Product Portfolio
GLOBAL MICROBIOME THERAPEUTICS MARKET
16
Figure 95 Figure 96 Figure 97 Figure 98 Pendulum Therapeutics Product Portfolio Caelus Health Product Portfolio Quorum Innovations Product Portfolio Sanofi S.A. Product Portfolio
Figure 99 Sanofi S.A. Overall Financials, Million, 2019-2021
Figure 100 Sanofi S.A. Net Revenue (by Segment), Million, 2019-2021
Figure 101 Sanofi S.A. Net Revenue by Region), Million, 2019-2021
Figure 102 Sanofi S.A. RD Expenditure, Million, 2019-2021
Figure 103 DermBiont, Inc. Product Portfolio
Figure 104 EnteroBiotix Ltd Product Portfolio
Figure 105 YSOPIA Bioscience Product Portfolio
Figure 106 Winclove Probiotics Product Portfolio
Figure 107 TargEDys Product Portfolio
Figure 108 Evelo Biosciences, Inc. Product Portfolio
Figure 109 Evelo Biosciences, Inc. Pipeline Products
Figure 110 Evelo Biosciences, Inc. Overall Financials, Million, 2019-2021
Figure 111 Evelo Biosciences, Inc. RD Expenditure, Million, 2019-2021
Figure 112 BiomX Product Portfolio
Figure 113 BiomX Pipeline Products
Figure 114 BiomX Overall Financials, Million, 2019-2021
Figure 115 BiomX RD Expenditure, Million, 2019-2021
Figure 116 Biomica Ltd. Pipeline Product
Figure 117 Scioto Biosciences, Inc. Product Portfolio
Figure 118 Scioto Biosciences, Inc. Pipeline Product
Figure 119 Lactobio A/S Product Portfolio
Figure 120 Lactobio A/S Pipeline Product
GLOBAL MICROBIOME THERAPEUTICS MARKET
17
List of Tables
Table 1 Global Microbiome Therapeutics Market Key Players Patent Portfolio
Table 2 Patent Expiration Analysis
Table 3 Partnership Landscaping
Table 4 Government Initiatives in Microbiome Therapeutics
Table 5 Impact of COVID-19 on Microbiome Therapeutics Developing Companies
Table 6 Key Players/Investors Portfolio
Table 7 Emerging Microbiome Therapeutics Products Pipeline
Table 8 Probable Potential First Entrants to Global Microbiome Therapeutics Market
Table 9 4D pharma plc Key Competitors
Table 10 Seres Therapeutics, Inc. Key Competitors
Table 11 Microbiotica Key Competitors
Table 12 Enterome Key Competitors
Table 13 Destiny Pharma plc Key Competitors
Table 14 Taisho Pharmaceutical Holdings Key Competitors
Table 15 AOBiome Therapeutics, Inc. Key Competitors
Table 16 Finch Therapeutics Group, Inc. Key Competitors
Table 17 Rebiotix Inc. Key Competitors
Table 18 MaaT Pharma Key Competitors
Table 19 Vedanta Biosciences Inc. Key Competitors
Table 20 Pendulum Therapeutics Key Competitors
Table 21 Caelus Health Key Competitors
Table 22 Quorum Innovations Key Competitors
Table 23 Sanofi S.A. Key Competitors
Table 24 DermBiont Inc. Key Competitors
Table 25 EnteroBiotix Ltd Key Competitors
Table 26 YSOPIA Bioscience Key Competitors
Table 27 Winclove Probiotics Key Competitors
Table 28 TargEDys Key Competitors
Table 29 Evelo Biosciences, Inc. Key Competitors
Table 30 BiomX Key Competitors
Table 31 Biomica Ltd. Key Competitors
GLOBAL MICROBIOME THERAPEUTICS MARKET
18
Table 32
Scioto Biosciences, Inc. Key Competitors
Table 33
Lactobio A/S Key Competitors
GLOBAL MICROBIOME THERAPEUTICS MARKET
19
Disclaimer
BIS Research Inc. provides valuable market
intelligence to an exclusive group of customers
in response to orders. The report is licensed
for the customer's internal use only and is
subject to restrictions set henceforth. This
document and its contents are confidential and
may not be further distributed, published or
reproduced, in whole or in part, by any medium
or in any form for any purpose, without the
express written consent of BIS Research Inc.
Customer will not disclose the contents of the
report, whether directly in any media or
indirectly through incorporation in a database,
marketing list, report or otherwise, or use or
permit the use of Information to generate any
statistical or other information that is or will
be provided to third parties or voluntarily
produce Information in legal proceedings.
Market reports are based on expectations,
estimates and projections as of the date such
information is available. Any recommendation
contained in this report may not be suitable for
all investors or businesses. The market
conclusions drawn are necessarily based upon a
number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of
the date of such statements, are inherently
subject to market fluctuations and business,
economic and competitive uncertainties and
contingencies
For more details regarding permission, please
contact us Email sales_at_bisresearch.com Tel 1
510 404 8135
GLOBAL MICROBIOME THERAPEUTICS MARKET
20
T E K R A M S C I T U E P A R E H
T E M O I B O R C I M L A B O L 20 G All
rights reserved at BIS Research Inc.
BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite
313 Fremont, CA 94538 -1686 E-mail
hello_at_bisresearch.com Call Us 1-510-404-8135
Global Delivery Center Tower B First Floor,
Tapasya Corporate Heights, Greater Noida
Expressway, Sector 126, Noida, U.P., 201303,
India Tel [phone]
www.bisresearch.com